Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 15, 2023

Primary Completion Date

July 10, 2025

Study Completion Date

July 10, 2025

Conditions

Lung Cancer

Interventions

DRUG

Aumolertinib

Aumolertinib treatment (110mg, p.o., QD) for 8 weeks

Trial Locations (1)

RECRUITING

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

All Listed Sponsors

lead

The First Affiliated Hospital of Guangzhou Medical University

OTHER